Chemical chaperone therapy for GM1-gangliosidosis
β Scribed by Y. Suzuki
- Publisher
- Springer
- Year
- 2008
- Tongue
- English
- Weight
- 195 KB
- Volume
- 65
- Category
- Article
- ISSN
- 1420-682X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Assays for synaptosomal highβaffinity uptake activity (glutamate, Ξ³βaminobutyric acid, norepinephrine), neurotransmitter synthesizing enzymes (choline acetyltransferase, glutamate decarboxylase, tyrosine hydroxylase), and endogenous neurotransmitters were performed in cats with advanced
b-Galactosidase deficiency is a group of lysosomal lipid storage disorders with an autosomal recessive trait. It causes two clinically different diseases, G M1 -gangliosidosis and Morquio B disease. It is caused by heterogeneous mutations in the GLB1 gene coding for the lysosomal acid b-galactosidas
On routine smears of blood and bone marrow of four patients with GM1 gangliosidosis type I, eosinophil granulocytes were unusually pale and contained faintly stained, unevenly spaced granules some of which were larger than normal and had abnormal ultrastructural appearance. The anomaly may represent
The human GLB1 gene produces two alternatively spliced transcripts that encode the lysosomal enzyme Ξ²-galactosidase (GLB1) and the elastin binding protein (EBP). Mutations at the GLB1 locus, which are responsible for the storage disorder GM1 gangliosidosis, may affect either both proteins or GLB1 on